Patient characteristics
| Patient characteristics . | Total,n = 38 . | BEACOPPbaseline, n = 15 . | BEACOPPescalated, n = 23 . | P . |
|---|---|---|---|---|
| Median age, y (range) | 26 (16-41) | 26 (18-35) | 26 (16-41) | .511* |
| Ann Arbor stage, no. (%) | ||||
| II B and risk factors† | 11 (29) | 4 (27) | 7 (30) | |
| III | 22 (58) | 9 (60) | 13 (57) | |
| IV | 5 (13) | 2 (13) | 3 (13) | > .999 |
| Risk factors, no. (%) | ||||
| ESR 30 or more | 20 (53) | 6 (40) | 14 (61) | .320‡ |
| B symptoms | 24 (63) | 8 (53) | 16 (70) | .492‡ |
| Large mediastinal mass | 15 (39) | 5 (33) | 10 (43) | .736‡ |
| Extranodal disease | 7 (18) | 2 (13) | 5 (22) | .681‡ |
| 3 or more lymph node areas involved | 33 (87) | 12 (80) | 21 (91) | .365‡ |
| Radiotherapy | 32 (84) | 13 (87) | 19 (83) | >.999 |
| Radiotherapy infradiaphragmal | 3 (8) | 1 (7) | 2 (9) | >.999 |
| Patient characteristics . | Total,n = 38 . | BEACOPPbaseline, n = 15 . | BEACOPPescalated, n = 23 . | P . |
|---|---|---|---|---|
| Median age, y (range) | 26 (16-41) | 26 (18-35) | 26 (16-41) | .511* |
| Ann Arbor stage, no. (%) | ||||
| II B and risk factors† | 11 (29) | 4 (27) | 7 (30) | |
| III | 22 (58) | 9 (60) | 13 (57) | |
| IV | 5 (13) | 2 (13) | 3 (13) | > .999 |
| Risk factors, no. (%) | ||||
| ESR 30 or more | 20 (53) | 6 (40) | 14 (61) | .320‡ |
| B symptoms | 24 (63) | 8 (53) | 16 (70) | .492‡ |
| Large mediastinal mass | 15 (39) | 5 (33) | 10 (43) | .736‡ |
| Extranodal disease | 7 (18) | 2 (13) | 5 (22) | .681‡ |
| 3 or more lymph node areas involved | 33 (87) | 12 (80) | 21 (91) | .365‡ |
| Radiotherapy | 32 (84) | 13 (87) | 19 (83) | >.999 |
| Radiotherapy infradiaphragmal | 3 (8) | 1 (7) | 2 (9) | >.999 |